Recursion Pharmaceuticals, Inc. $RXRX Stake Cut by Amova Asset Management Americas Inc.

Amova Asset Management Americas Inc. lessened its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 8.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,465,858 shares of the company’s stock after selling 701,887 shares during the quarter. Amova Asset Management Americas Inc. owned approximately 1.72% of Recursion Pharmaceuticals worth $36,359,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of Recursion Pharmaceuticals by 10.3% during the 3rd quarter. Vanguard Group Inc. now owns 39,780,153 shares of the company’s stock valued at $194,127,000 after acquiring an additional 3,708,975 shares in the last quarter. ARK Investment Management LLC increased its position in Recursion Pharmaceuticals by 1.7% in the 3rd quarter. ARK Investment Management LLC now owns 33,545,499 shares of the company’s stock worth $163,702,000 after purchasing an additional 556,868 shares during the last quarter. Geode Capital Management LLC increased its position in Recursion Pharmaceuticals by 20.7% in the 2nd quarter. Geode Capital Management LLC now owns 7,776,408 shares of the company’s stock worth $39,353,000 after purchasing an additional 1,332,428 shares during the last quarter. Norges Bank purchased a new stake in shares of Recursion Pharmaceuticals during the 2nd quarter worth about $16,040,000. Finally, First Trust Advisors LP lifted its holdings in shares of Recursion Pharmaceuticals by 82.3% during the 2nd quarter. First Trust Advisors LP now owns 1,880,290 shares of the company’s stock valued at $9,514,000 after buying an additional 848,791 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Insiders Place Their Bets

In related news, Director Blake Borgeson sold 220,000 shares of the stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $4.20, for a total transaction of $924,000.00. Following the completion of the transaction, the director owned 6,429,863 shares in the company, valued at approximately $27,005,424.60. This represents a 3.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Najat Khan sold 124,403 shares of Recursion Pharmaceuticals stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $4.41, for a total transaction of $548,617.23. Following the sale, the insider directly owned 611,135 shares of the company’s stock, valued at $2,695,105.35. The trade was a 16.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 599,212 shares of company stock valued at $2,562,550 in the last quarter. 8.43% of the stock is currently owned by insiders.

Recursion Pharmaceuticals Trading Up 2.8%

Shares of NASDAQ RXRX opened at $3.64 on Thursday. The company has a quick ratio of 5.50, a current ratio of 5.50 and a debt-to-equity ratio of 0.01. The company’s fifty day moving average is $4.13 and its 200-day moving average is $4.65. Recursion Pharmaceuticals, Inc. has a twelve month low of $2.98 and a twelve month high of $7.18. The stock has a market cap of $1.89 billion, a price-to-earnings ratio of -2.46 and a beta of 0.97.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, February 25th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.07. The firm had revenue of $35.54 million for the quarter, compared to the consensus estimate of $24.56 million. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The business’s quarterly revenue was up 671.7% on a year-over-year basis. During the same period last year, the company posted ($0.53) EPS. Equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on the stock. JPMorgan Chase & Co. raised shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $10.00 to $11.00 in a research report on Wednesday, December 17th. Bank of America cut their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, January 22nd. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Needham & Company LLC restated a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 26th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.